复发难治性非霍奇金氏淋巴瘤的dhap方案治疗疗效观察

《复发难治性非霍奇金氏淋巴瘤的dhap方案治疗疗效观察》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、复发难治性非霍奇金氏淋巴瘤的DHAP方案治疗疗效观察郴州市第一人民医院中心医院湖南郴州423000【摘要】目的：观察DHAP方案治疗复发难治性非霍奇金氏淋巴瘤的疗效及安全性。方法：选择我科收治的36例复发难治性非霍奇金淋巴瘤患者，将所有研究治疗第Id予以顺铂85mg/cm2,在避光的条件下行静脉滴注，同时予以阿糖胞苷2g/m2,12h/次，静脉滴注；在治疗第l-4d予以地塞米松40mg/d，静脉滴注。观察治疗后患者的疗效，并进行安全性评价。结果：所有患者均完成2个治疗周期后进行疗效及安全性评定，其中3

2、6例患者中CR者12例、PR者12例、NC者10例、PD者2例，有效率66.7%;不良反应以血液系统毒性为多，其中贫血者8例、血小板降低者7例以及白细胞减少者7例，共计61.1%。与治疗前比较，治疗后患者的SAS评分均降低明显，FACT评分中PWB、SWB、EWB、FWB评分均增加明显，差异異统计学意义(P<0.05)o结论：DHAP方案治疗复发难治性非霍奇金氏淋巴瘤疗效较好，安全性尚可，可较好的改善患者的焦虑情绪,提高牛.活质量。【关键词】复发难治性；非霍奇金氏淋巴瘤；DHAP方案；疗效；安全

3、性ObservationoncurativeeffectsofDHAPschemeintreatmentofrecurrentrefractorynon-Hodgkin’slymphomaZhuPing’an(ChenzhouCenterHospital(FirstPeople’sHospital),HunanChenzhou,423000)[Abstract]Objective：ToobservethecurativeeffectsandsafetyofDHAPs

4、chemeintreatmentofrecurrentrefractorynon-Hodgkin’slymphoma.Methods：36patientswithrecurrentrefractorynon-Hodgkin’slymphomawereselectedfromourdepartment.AIIofthepatientsweregiven85mg/cm2cisplatinviaintravenousdripinthedarkonthefirstdayoftreatm

5、ent，whilethepatientsweregiven2g/m2cytarabineviaintravenousdrip,12heachtime.Thepatientsweregiven40mg/ddesamethasoneviaintravenousdriponl-4doftreatment.Patients’curativeeffectswereobservedandweregivensafetyevaluation.Results：Allpatientscompleted2tre

6、atmentcoursesandweregivenevaluationoncurativeeffectsandsafety.Among36patients,CRresultswerein12cases，PRin12cases,NCin10cases,andPDin2cases，witheffectiverateof66.7%；adversereactionwasgivenprioritytotoxicityofbloodsystem，including8casesofanemia，7casesofde

7、creasedplateletand7casesofleucopenia,atotalof61.1%.Comparedwithbeforetreatment,SASscoresweresignificantlydecreasedinpatientsaftertreatment,butscoresPWB，SWB,EWB，andFWBinFACTscaleweresignificantlyincreased，withstatisticallysignificantdifference(P<0.05)

8、.Conclusion：DHAPschemeiseffectiveandsafeintreatmentofrecurrentrefractorynon-Hodgkin’slymphoma,whichcanbetterimprovethepatient’sanxiety，andimprovethequalityoflife.【keywords】Recurrenceofrefractory；Non-hodgkin'slymphoma.